Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJ2Q6H)

Drug Name
MK-7288 Drug Info
Indication
Disease Entry ICD 11 Status REF
Excessive daytime sleepiness MG42 Phase 1 [1]
Cross-matching ID
PubChem CID
16659778
TTD Drug ID
DMJ2Q6H

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H3 receptor (H3R) TT9JNIC HRH3_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Histamine H3 receptor (H3R) DTT HRH3 3.225 3.399 3.17 3.027
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Excessive daytime sleepiness
ICD Disease Classification MG42
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H3 receptor (H3R) DTT HRH3 3.62E-02 -0.09 -0.22
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01092780) Pharmacodynamics and Efficacy of MK7288 (MK-7288-010). U.S. National Institutes of Health.
2 Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients. J Clin Pharmacol. 2013 Dec;53(12):1294-302.